Skip to main content
Clinical Trials/JPRN-UMIN000008844
JPRN-UMIN000008844
Completed
Phase 4

Evaluation of clinical guideline and establishment of evidence for the diagnosis and treatment of primary hyperaldosteronism in Japan. - PHAS-J3

ational Hospital Organization0 sites2,641 target enrollmentSeptember 5, 2012

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Primary aldosteronism
Sponsor
ational Hospital Organization
Enrollment
2641
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 5, 2012
End Date
September 30, 2017
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
ational Hospital Organization

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\)pregnant patients 2\)patients taking aldosterone antagonist within the last one month 3\)patients with the following diseases: (1\)secondary hypertension (renal hypertension,renovascular hypertension, primary aldosteronism, Cushing's syndrome, pheochromocytoma, etc) (2\)patients whom the attending doctors decides not suitable for the entry because of the unstable stage of the following complications: coronary diseases, arrhythmia, severe valvular diseases, cerebrovascular diseases, acute and chronic renal failure (serum Cr higher than 3mg/dl), acute and chronic liver diseases 4\) Patients whom the attending doctor decides not suitable for the entry of the study.

Outcomes

Primary Outcomes

Not specified

Similar Trials